macular oedema


Also found in: Dictionary, Thesaurus.
Related to macular oedema: Macular edema

macular oedema

Retinal thickening due to the accumulation of fluid, which occurs in diabetic retinopathy, visualised by a binocular slit lamp or stereoscopic fundus photography. While macular oedema has few visual consequences, other than distortion of central vision, it is often accompanied by hard exudates, which are associated with loss of vision.

Management
Laser photocoagulation may be used to manage branch retinal vein occlusion (BRVO); it is ineffective for central retinal vein occlusion (CRVO).

oedema, cystoid macular (CMO) 

Oedema and cyst formation of the macular area of the retina. It may occur as a result of, or be associated with, systemic vascular disease, retinal vein occlusion, diabetic retinopathy, uveitis, hypertensive retinopathy, retinitis pigmentosa and following some ocular surgery such as vitreoretinal, photocoagulation, glaucoma procedures and especially cataract surgery. When cystoid macular oedema follows cataract surgery it is called the Irvine-Gass syndrome and it is sometimes accompanied by intraoperative vitreous loss or vitreous adhesion to the iris or to the corneoscleral wound. Visual acuity is affected initially but recovers in the majority of cases. In some cases antiinflammatory therapy may help in restoring visual acuity and in other cases the vitreous adhesion may be disrupted with a Nd-Yag laser.
References in periodicals archive ?
To be able to understand the potential impact of cystoid macular oedema on visual outcome (Group 2.
The decision announced today represents the first NICE recommendation for a licensed treatment for macular oedema associated with RVO and with it NICE has made available to retinal specialists and their patients an important treatment for this potentially devastating condition," said Mr.
The Macular Oedema Market is Forecast to Show Modest Growth to 2016
Approximately 400 patients suffering from macular oedema following BRVO of <90 days duration will be enrolled into the COMO study and randomised to receive treatment with either OZURDEX(R) or ranibizumab.
Statistics report that chronic diabetic macular oedema affects around 14% of people with diabetes in the UK.
FRIMLEY, England, January 13, 2011 /PRNewswire/ -- Novartis Pharmaceuticals UK Ltd today announced that Lucentis(R) (ranibizumab) is being launched in the UK for the treatment of visual impairment due to diabetes, specifically diabetic macular oedema (DMO).
However, in the past few months, the National Institute for Health and Care Excellence (NICE) has approved it for patients with macular oedema as a result of diabetic retinopathy.
FRIMLEY, England, January 11, 2011 /PRNewswire/ -- Novartis Pharmaceuticals UK Ltd today announced that Lucentis(R) (ranibizumab) is being launched in the UK for the treatment of visual impairment due to diabetes, specifically diabetic macular oedema (DMO).
The NATIONAL Institute for Health and Clinical Excellence (NICE) has recommenced that Lucentis is approved to treat people with visual impairment due to macular oedema within the NHS in England and Wales.
This causes macular oedema and formation of hard (lipid) exudates (Figure 2).
Most significant are the basic concepts of macular oedema presented in Chapter 1, the extensive account of diabetic macular features (Chapter 6) and the succinct description of therapeutic rationale in Chapter 4.
NICE, the NHS organisation that makes recommendations for the use of medications in the Health Service, is reviewing two new treatments, one for diabetic macular oedema, a type of diabetic retinopathy, and another one for retinal vein occlusion.